Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Cationic Liposome HAI + Systemic Therapy in Colorectal Liver Metastases
NCT07117435Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Paclitaxel Micelles for Injection in colorectal liver metastases (CRLM) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Incidence of Dose-Limiting Toxicity and Incidence and Severity of Adverse Events and Serious Adverse Events up to 1 year. Started May 2025; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT07117435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117435.